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ing rodent study design in biological development and (iv) consolidating approaches in developmental
and reproductive toxicology. Through providing a forum for open discussion of novel proposals, review-
ing current research and obtaining expert opinion in each of the four areas, the authors have developed
recommendations on good practice and future strategy.
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Fig. 1. Examples of in vitro and in vivomethods. Speciﬁc biological mechanisms and holistic bioassays are represented separately. hERG, human Ether-a-Go-go Related Gene;
CTPs, phosphocholine cytidylyltransferase; DART, developmental and reproductive toxicity.
K.L. Chapman et al. / Regulatory Toxicology and Pharmacology 66 (2013) 88–103 89appropriate animal use in toxicology studies, with the continued
goals of not only improving their predictive value but also reducing
overall animal use and enhancing animal welfare.
Generally, risk assessment can be viewed as a process by which
information from various sources (e.g. in vitro, in silico, and in vivo
studies) is combined to characterize a particular chemical or
molecular entity. Ideally, chemical and drug development would
be front-loaded with experiments that can deﬁnitively select safe
compounds as quickly as possible. As data accumulates to support
the predictive validity of in silico and in vitro studies for human
safety, these techniques will enable compounds to be deselected
earlier in development, thereby limiting the need for animal test-
ing. The replacement, reﬁnement, and reduction of animals in re-
search (the 3Rs) is a well-established concept, originally
described in 1959 (Russell and Burch, 1959). Throughout the
1960s and 1970s, the idea that there may be alternatives to ani-
mals in research continued to increase in visibility, until ﬁnally
gaining signiﬁcant momentum during the 1980s when govern-
ments, academia and industry became more involved (Stephens
et al., 2001). However, it is only now 50 years since the initial pub-
lication that the 3Rs are truly coming of age, with growing recog-
nition of their beneﬁts and widespread efforts to identify new
opportunities for implementation.
In order to identify opportunities to further reduce animal use
and improve efﬁciency in drug development, an international
workshop was convened to catalyze discussion on various related
themes, including: (1) accelerating the progress and uptake of
in vitro methods, (2) incorporating the latest science into safety
pharmacology assessments, (3) optimizing designs for rodent stud-
ies to support the development of biologicals, and (4) consolidating
various approaches and endpoints in developmental and reproduc-
tive toxicology. Representatives from international pharmaceutical
companies, contract research organizations, and regulatory agen-
cies also discussed potential concerns around regulatory accep-tance when making decisions using novel, rather than traditional
approaches. In the 12 months since the workshop, drawing on
the expertise of the authors and others present, we have worked
towards some practical solutions to common challenges with
implementing and improving 3Rs practices in these various areas.
Further, expert advice on how new ideas and approaches may be
effectively integrated into the constantly evolving model of drug
development is discussed. Although this paper is focused on the
pharmaceutical industry, participants from the agrochemical
industry have also participated, and we have also drawn on their
experiences to identify cross-sector parallels.2. Predicting human toxicology using in vitro methods; can we
accelerate progress?
There are multiple drivers for the development of new in vitro
approaches to replace animal bioassay testing including scientiﬁc
and technological advances, increased focus on animal welfare,
and legislative changes. Position papers in Europe and the US
(Schumann, 2002; EEC, 1986; Louhimies, 2002), European legisla-
tion for the testing of chemicals and cosmetics (EEC, 1976; REACH,
2006) and establishment of validation centers for alternative test
methods illustrate the interest in this area from the international
community of scientists, regulators and government agencies.
Additionally, the European Medical Agency (EMA) recognized the
increased use of in vitro methods with a recent revision of their
concept paper on the replacement of animal studies with in vitro
tests (EMA, 2012). One purpose of this paper was to more clearly
deﬁne the process for regulatory acceptance of alternatives, includ-
ing the need for formal validation studies on some occasions but
proof of scientiﬁc validity on others.
The intended goal of this section is to provide expert opinion on
the smooth integration of appropriate in vitro tests into current
Table 1
Examples of in vitro methods enhancing drug development decisions.
Subject area In vitro model
Dermal Absorption Human and animal excised skin
DMPK – metabolite
proﬁling
Human and animal subcellular fractions and
hepatocytes
DMPK – drug/drug
interactions (DDI)
Human hepatic subcellular fractions, hepatocytes
and transfected cell systems
Drug induced liver
injury (DILI)
Human and animal subcellular fractions and
hepatocytes
Pulmonary toxicity MucillAir™
EpiAirway™
Renal toxicity Primary human proximal tubule epithelial cells
Endocrine disruption Recombinant hES
Cardiovascular toxicity iCell cardiomyocytes
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these data to reduce animal use and reﬁne in vivo studies.
2.1. Challenge: lack of regulatory acceptance of in vitro methods can
limit their usefulness in replacing and reducing animal use
2.1.1. Expert solution: mechanistically-based in vitro methods can be
used at all stages of pharmaceutical and chemical development to
reduce and inform in vivo studies
There are two general classes of biological methods used in the
discovery and development of new products: holistic bioassays
and methods that evaluate speciﬁc biological mechanisms. In vitro
and in vivo examples of each exist (Fig. 1). The regulatory valida-
tion process of in vitro methods (bioassay or mechanistic) to re-
place an in vivo regulatory bioassay may deter scientists from
developing them. However, not all scientiﬁcally validated method-
ologies require regulatory acceptance. By focusing on the intended
use, the scientiﬁc validation becomes signiﬁcantly less daunting.
The emergence of novel in vitro methods has greatly enhanced
decision making in drug development, allowing the selection and
progression of molecules with maximum efﬁcacy and minimal tox-
icity. Some examples of such models in use within industry are
shown in Table 1. Further, mechanism-based models show the po-
tential of translation across species (including human), whereas
bioassay-based models may have limited translation only within
speciﬁc contexts. If in vitro screens are targeted towards elucidat-
ing mechanisms of action or mechanisms of toxicity and are devel-
oped based on directed hypotheses, they can be used to provide
valuable safety information early in development. For example,
considerable progress has recently been made in alternative assays
to detect skin sensitization potential. A vision for how mechanisti-
cally-based non-animal methods may be more widely imple-
mented in toxicity assessment was presented in a 2007 NRC
report (US National Research Council, 2007). The central concept
was to leverage new in vitro and computational tools to allow sci-
entists to delineate ‘toxicity pathways’ that could then be extrapo-
lated for use in human risk assessment.
In certain circumstances regulatory acceptance will be neces-
sary to prevent animal studies being carried out in addition to
the in vitro tests. In these cases, a number of principles must be
met and the mechanistic relevance of the in vitro endpoint to the
in vivo effect and the relationship between the in vivo outcome
and in vitro test results must be demonstrated. The uses and limi-
tations of the in vitro method must also be clearly deﬁned. For full
regulatory establishment and adoption of a new method, eight to
nine years is typical:
 1 year to conﬁrm funding, design protocols and assemble the
teams of scientists.
 3 years to undertake the research.
 4–5 years for pre-validation, validation and acceptance.There are opportunities to streamline this process. For example,
by sharing cross-company experiences, we can more readily iden-
tify the predictive assays that merit further validation and also
identify those that should be dropped. Such an experience-sharing
initiative may also identify gaps for future research investment.
Additional information may be gained by learning how failed com-
pounds behaved in in vitro tests, and through identiﬁcation of the
precise mechanisms that underpinned those failures (so they can
be targeted and avoided in the future). We should also be encour-
aged by the success of test methods that have been validated and
accepted (Table 2). The International Cooperation on Alternative
Test Methods (ICATM) is also aimed towards supporting more ra-
pid acceptance of new methods and may serve as a resource for
validation.2.2. Challenge: it can be difﬁcult to put data from in vitro methods into
context
2.2.1. Expert solution: increased use of technologically advanced
in vitro methods will generate a rich data and experience base that will
increase translational conﬁdence
The perceived lack of conﬁdence in the translational attributes
of in vitro methods may be due to fear of change, limited historical
data, concerns over how predictive they may be of the in vivo sit-
uation, and lack of clarity regarding whether the method is mech-
anism or bioassay based. A shift in how in vitro methods are
viewed is needed to overcome this hurdle. For instance, an
in vitro test may not completely replicate the equivalent in vivo
bioassay but it may answer a speciﬁc question in a different way.
Additionally, 3D cell and tissue models bring us ever closer, phys-
iologically to the in vivo situation. In vitro bioassay methods
attempting to predict in vivo bioassays will be susceptible to all
of the criticisms and concerns associated with the latter, whereas
mechanism-based assays may provide better data upon which
decisions may be made.
The incentive to use novel in vitro methods is high due to the
advantages of being able to manipulate the test system (Fig. 2)
which may provide a more thorough understanding of potential
mechanisms of toxicity and the human and animal response to
exposure to foreign chemicals. As technically validated mecha-
nism-focused in vitro methods are used more widely and more
data are accrued, scientiﬁc conﬁdence will increase. This is perhaps
best exempliﬁed by the in vitro hERG assay, which has become a
key tool in predicting the clinical risk of QT prolongation associated
with new chemical entities (Redfern et al., 2003; Moller, 2010; Pic-
cini et al., 2009). Another is the use of mechanism-focused genetic
toxicity tests (e.g. Ames Test; mouse lymphoma) to detect poten-
tial to cause genetic mutation (by direct interaction with the
DNA itself or by indirect mechanisms) in drug discovery, thereby
all but eliminating clinical development failures for positive car-
cinogenicity bioassay results related to genotoxicity.2.3. Challenge: in vitro methods may be used for compound screening,
however they have little impact on the overall number of animals used
in regulatory toxicology
2.3.1. Expert solution: predictive toxicology and more accurate
compound selection will avoid the use of animals for drugs destined to
fail later in development
The high failure rate of candidate drugs after the decision to be-
gin regulatory (Good Laboratory Practice (GLP)) toxicology testing
arguably represents the largest opportunity to reduce overall ani-
mal use across the pharmaceutical industry. Candidate drug attri-
tion after ﬁrst in man clinical trials have been carried out is
approximately 90% (Kola and Landis, 2004; Khanna, 2012). In other
Table 2
Table of validated and accepted in vitro test methods.
Subject area Relevant guidance documents(s)
Genetic toxicology OECD 471, 473, 475, 476, 487
Skin absorption OECD 428
Skin corrosion OECD 430, 431, 435
Phototoxicity OECD 432
Skin irritation OECD 439
Ocular irritation and
corrosion
OECD 437, 438
Endocrine disruption OECD 455, 456
Reproductive toxicology OECD 414
Safety pharmacology ICH S7B
Drug metabolism and
pharmacokinetics
(DMPK)
CPMP/EWP/560/95/Rev.1, FDA draft guidance
on drug interaction studies, EMA draft
guidance on the investigation of drug
interactions
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phase I will not achieve marketing approval. However, much of
the regulatory animal testing is front-loaded, and must be com-
pleted before clinical trials may proceed. Therefore, when candi-
dates fail in clinical development, the animal testing associated
with those candidates to their point of failure could potentially have
been avoided. Reducing candidate drug attrition through better pre-
dictive in vitro assays, can reduce overall animal use in severalways.
First, studies previously performed on compounds destined to be
dropped are no longer performed because these compounds have
been screened out during discovery. Second, as clinical attrition is
decreased due to better screening, clinical pipelines are ﬁlled with
more compounds progressing towards marketing authorizations,
reducing the need for more candidates and their associated animal
studies. Finally, as overall probability is increased that new candi-
dates will achieve marketing approval, the overall size of both dis-
covery and development pipelines is reduced, delivering furtherFig. 2. How in vitro tests are used at the different stages of drug development to reduce a
product maintenance.savings in animal use. All this is achievable with improved in vitro
and in silico tests to select and/or drive design of compounds target-
ing speciﬁc mechanisms needed for therapeutic efﬁcacy, whilst
avoiding those associated with toxicity.
Currently, although in vitro tests are increasingly being used for
compound selection, the overall use of animals has remained the
same as a relatively constant number of drugs continue to be se-
lected for in vivo studies (UK Home Ofﬁce, 2012). However, with
more predictive in vitro tests better decisions can be made in selec-
tion of candidate drugs, avoiding the redundant or unnecessary use
of animals. Use of in vitro techniques in compound (de)selection
will improve the quality of candidate drugs, decrease toxicologi-
cal/preclinical attrition, and reduce the number of animals used
in non-clinical safety assessment. For example, early detection of
genotoxicity in vitro could preclude the further development of
these new chemical entities, as is the case with European cosmet-
ics (EEC, 1976).
Focusing on the traditional view of replacement as a 1:1
replacement of an in vivo test with an in vitro test (particularly
an in vitro bioassay for an in vivo bioassay) has arguably prevented
opportunities to reduce animal use. In addition, we should be more
open to how in vitro studies can be used to avoid animal studies
and/or improve animal welfare. Such a strategy is recognized in
OECD Test Guideline no. 404 (Acute Dermal Irritation/Corrosion),
which recommends the conduct of in vitro assays (OECD TG 430
and 431) to limit the severity of toxicity for compounds that pro-
gress to in vivo evaluation. Similarly, OECD TG 437 is designed to
identify substances that are ocular corrosives or severely irritating
to the eye. Substances that are negative in this test would be re-
quired to undergo further in vivo testing to allow accurate classiﬁ-
cation. Finally, in vitro studies can be used to improve the
predictive value of in vivo toxicology studies by supporting the
selection of an appropriate animal species, ensuring that testing
is not conducted in species that lack human relevance.nimal use. Hit identiﬁcation, lead identiﬁcation, lead optimization, pre-nomination,
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The inclusion of safety pharmacology investigations in regula-
tory drug safety studies was ﬁrst described in the International
Conference for Harmonization (ICH) M3 and S6 guidance issued
in 1997 (ICH, 1997a,b). While these initial documents referred to
the importance of directed safety pharmacology studies, speciﬁc
guidance governing the conduct of these studies was not provided
until the release of ICH S7A in 2001 which provided speciﬁc recom-
mendations for the conduct of safety pharmacology studies for hu-
man pharmaceuticals (ICH, 2001). This was followed in 2005 by
the release of the S7B guidance, which addressed the nonclinical
investigation of potential delayed cardiac repolarization (QT inter-
val prolongation) by human pharmaceuticals (ICH, 2005a) and the
ICH E14 guidance which addressed the clinical evaluation of QT
prolongation (ICH, 2005b).
To meet current regulations, safety pharmacology studies for
new chemical entities typically assess effects on the respiratory
(rodent), cardiovascular (non-rodent) and central nervous system
((CNS); rodent). In order to identify potential undesirable pharma-
codynamic properties that may have relevance to human safety,
conscious, unrestrained animals are the preferred nonclinical mod-
el. Initial studies are typically single dose studies that include, and
exceed, the expected therapeutic range of a novel pharmaceutical
agent. Often, a tiered approach is used to address relevant concerns
across the core battery of regulatory safety investigations. As noted
in the ICH guidance, these studies may be performed as either
standalone studies or incorporated into toxicity studies performed
prior to ‘ﬁrst in man’ administration.
This section investigates opportunities to improve efﬁciency in
safety pharmacology studies by ensuring appropriate statistical
analysis and state-of-the-art science are efﬁciently incorporated
into practice. We identiﬁed some of the key challenges impacting
advances in this area and discuss how these may be overcome.3.1. Challenge: there can be signiﬁcant delays between scientiﬁc and
technological advances and changes in company and regulatory
practice
3.1.1. Expert solution: increase information sharing between
pharmaceutical, contract research organizations and regulators
through an industry ‘champion’
One area with the potential to reduce animal use is in combin-
ing studies, such as the incorporation of safety endpoints into tox-
icology studies that are already being carried out as part of an
investigational new drug (IND) enabling program or clinical trial
application (CTA), including dose range ﬁnding and 28-day toxicol-
ogy studies. Animal use may be reduced by replacing standalone
safety pharmacology studies with integrated toxicology studies,
which is consistent with current ICH guidance (ICH, 2009). When
studies are combined, animal use may be reduced by 20–40%.
Although this is a common approach during the development of
biologics and anti-cancer therapeutics, many companies are reluc-
tant to implement this approach for other types of drugs without
evidence that regulators will accept it in practice. This concern is
based on the impact of possible confounding factors, such as the
inﬂuence of pharmacokinetic/toxicokinetic (PK/TK) blood collec-
tions from main study animals on functional safety parameters.
However, this may be overcome by multiple phase studies that
ﬁrst assess safety pharmacology parameters followed by other pro-
cedures (e.g. blood collection) in the same animals.
Advances in scientiﬁc knowledge also need to be efﬁciently
incorporated into regulatory practice and the relevant information
shared with the regulators to foster broad acceptance. The Safety
Pharmacology Society recently released a cardiovascular ‘‘BestPractices’’ document which offers recommendations with the po-
tential to further reduce animal use while improving experimental
accuracy (Leishman et al., 2012). As noted in this document, our
understanding of the fundamental nature of the QT interval has
evolved since the release of the S7B guidelines. The QT interval is
now understood to vary not only with heart rate (addressed in
S7B), but also to demonstrate profound heart rate-independent
variability. This paper concluded that the so-called generic QT
rate-corrections such as Bazett (1920) and Fridericia (1920) were
not suitable for use in studies involving nonhuman primates, rec-
ommending instead the use of individual QT rate-corrections.
Importantly, current regulatory guidance does not address this.
As such, regulatory safety studies are still being conducted using
QT rate-corrections which have been demonstrated to be inade-
quate. Such studies constitute a poor use of animals and, in the
worst case, may fail to accurately detect human risk. These circum-
stances highlight the absolute requirement for investigators and
regulators to stay abreast of contemporary scientiﬁc developments
that may alter the fundamental understanding of a particular mod-
el system. Such developments must then be expeditiously incorpo-
rated into the applicable regulatory guidance.
To accelerate progress in this area we suggest that an industry
champion assume responsibility for identifying novel methods
and approaches that have the potential to be accepted by regulators.
The championwould lead a group comprised of a number of compa-
nieswhoare abreast of the latest science in safetypharmacologyand
would provide a consensus opinion on appropriate practice. This
group would also provide a link between industry and regulators
to enable greater interaction and data-sharing between the two
groups. The champion concept is not unique to safety pharmacology
and could be applied to all areas discussed in this paper.
3.2. Challenge: in order to achieve adequate statistical power in
experiments, more animals must be used
3.2.1. Expert solution: technological advances combined with
improved study designs enable reductions in animal use and better
data
Underpowered experiments do not accurately inform us about a
given risk or safety margin. When investigators fail to properly
incorporate measurement error and statistical power in their study
design and interpretation, experiments may need to be repeated.
However, an increase in animal use (e.g. group size) is not neces-
sary to increase statistical power in many cases. By employing
more sensitive measurement techniques, such as chronic or jack-
eted telemetry, raw measurement error can be reduced. The corre-
sponding improvement in statistical power reduces the number of
observations necessary to establish a given effect. Similar gains
have been realized as researchers advance the state-of-the-art for
particular endpoints of interest (Glueck et al., 2008). For instance,
recent investigations have highlighted that more frequent ECG
measurements are necessary for accurate quantiﬁcation of QT
interval (Holzgrefe et al., 2007).
The Safety Pharmacology Society identiﬁed study power (pro-
spective and retrospective) as a key concern during its discussions
on optimizing the precision, power, design, execution, and data
exploitation from safety pharmacology assays. The following
example demonstrates the importance of appropriate study design
and statistical analysis in a contemporary safety pharmacology
study to avoid increasing the number of animals needed to get a
statistically signiﬁcant result. Jacketed external telemetry (JET) al-
lows the direct incorporation of continuous ECG (noninvasive) and
blood pressure (minimally invasive) monitoring in repeat-dose
toxicology studies (Cavero, 2010). This technology provides the
ability to obtain high ﬁdelity continuous cardiovascular measure-
ments in long-term repeat-dose models. However, new technology
Fig. 3. The stages of the reproductive life cycle needed to assess reproductive and developmental effects of toxicity in animals.
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This was highlighted by the impact of the jackets on heart rate.
Each animal exhibited a unique jacket acclimatization pattern,
which had to be accommodated in the experimental design and
interpretation. Adequate statistical power allows the investigator
to correctly eliminate false positive and false negative results,
improving not only the quality of the overall safety assessment,
but assuring that any unnecessary animal use is eliminated. Peers
et al. argue that the systematic incorporation of improved statisti-
cal input into preclinical experiments will reduce attrition and im-
prove translation of ﬁndings to the clinic (Peers et al., 2012).
3.3. Challenge: safety pharmacology may be perceived as a box
checking exercise with a one size ﬁts all approach
3.3.1. Expert solution: good science and therapeutic indication should
drive decisions at both program selection and regulatory levels
Safety pharmacology data provide critical information in early
development and discovery phases and are often used to make
decisions on whether a potential drug should be discontinued from
development, or not. However, the assumption that most pharma-
cological effects on the CNS, respiratory, or cardiovascular systems
are accurately detected at the early stages of development can lead
to ‘box checking’ in later studies, just to meet regulatory
requirements.
The Animal Model Framework and other groups have been col-
lecting data to analyze the predictivity of cardiovascular, respira-
tory, and CNS preclinical studies; this information will be used to
improve safety pharmacology models and ensure that current ani-
mal models add value to the decision making process (Ewart et al.,
2012; Valentin et al., 2009).
As safety tolerances differ for chronic and acute life-threatening
indications, another approach may be to separate acute safety con-
cerns from long-term risk by therapeutic indication. Current safety
pharmacology guidance does not address this distinction. Looking
to the future, it may be feasible to broadly redeﬁne safety assess-
ment paradigms by indication. In principle, this strategy could re-
duce the number of preclinical safety studies needed for a life-
threatening indication while retaining the current guidance for
drugs designed for chronic use. Coupledwith the improved sensitiv-ity made possible with current and emerging technologies, this fur-
ther demonstrates the importance of 3Rs in human risk assessment.
4. Developmental and reproductive safety testing; consolidating
opportunities in the current environment
Guidelines for developmental and reproductive toxicity (DART)
studies were ﬁrst issued by the US in 1966 (US FDA, 1966), ac-
cepted in the UK in 1975 (Committee on Safety of Medicines,
1975) and Japan in 1984 (Tanimura et al., 1989). The early guide-
lines suggested using over 10,000 (adults, juveniles and fetuses)
animals per drug to assess reproductive toxicity. One driver for
the establishment of the International Conferences on Harmoniza-
tion (ICH) was to produce guidelines that used fewer animals while
still providing an adequate evaluation of the outcome of an expo-
sure to a drug/chemical at any point in the reproductive life cycle
(Fig. 3). The ICH S5 guidance (ICH, 1994) on the testing of medi-
cines for reproductive toxicity was the ﬁrst harmonized guideline
for nonclinical testing to be ﬁnalized. This harmonization halved
the numbers of animals required for evaluating a DART hazard of
a new pharmaceutical to approximately 5000 animals.
Since ICH S5 was ﬁrst published there has been much work to
further reduce animal use for DART studies (Barrow, 2009; Stew-
art, 2009). This section consolidates some of the opportunities to
make DART studies more efﬁcient and explores how best to imple-
ment them in current development programs.
4.1. Challenge: there may be some circumstances where DART studies
do not provide additional value
4.1.1. Expert solution: timely interpretation of all available results can
identify cases where DART studies can be avoided without
compromising human safety
Traditionally, to assess reproductive toxicity of a new chemical
entity, a rodent study for male and female fertility, studies in two
species for developmental toxicity (embryo fetal development
(EFD)) and a rodent study for the peri-postnatal toxicity study
(PPND) are usually required. However, it may be possible to make
decisions early in drug development that would prevent initiation
of a full EFD study in two species. ICH S5 guidance recommends
Fig. 4. Figure showing a combined male and female fertility and embryofetal development study. This can reduce animal use by 20% per compound. GD, gestational day.
Fig. 5. Timing of studies to reduce animal use in reproductive toxicology studies due to fewer projects in later phases. DRF, dose range ﬁnding; EFD, embryofetal
development.
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20 litters per group in the EFD study. However, dose range ﬁnding
(DRF) studies in pregnant animals are generally used prior to the full
EFD study to ensure appropriate dose selection. If a positive result
with clear evidence of developmental toxicity is found in the DRF
EFD study then it is unlikely that another study will provide addi-
tional information for safety and labeling. This is especially true
when TK parameters are collected in the DRF study so that exposure
can be measured. In cases where sufﬁcient data are available from
general toxicity studies, a DRF study in pregnant animals may be
unnecessary. For example, in non-human primates (NHPs) a DRF
study is not generally conducted prior to the deﬁnitive EFD or PPND
study(s). However, there are examples of low toxicity compounds
which maybe very toxic to pregnant animals or to the conceptus,
which makes this approach risky in terms of reducing animal use.
In vitro methods may also currently be underutilized to deter-
mine species relevance. For instance, when in vitro metabolismstudies are being conducted for a small molecule, inclusion of rab-
bit microsomes along with the standard species would provide
data on the appropriateness of the rabbit for an EFD study. This
could lead to de-selection of the rabbit in certain circumstances.
Alternative developmental toxicity assays, including whole em-
bryo culture, embryonic stem cells, zebraﬁsh and several other
promising assays are being used to screen compounds and study
toxicity mechanisms and pathways (Chapin et al., 2008; Brannen
et al., 2010). These assays are unlikely to completely replace ani-
mal EFD studies in the near future, but it is clear that the informa-
tion gained is providing valuable information in predicting human
hazard. Enhancements of these assays by the addition of molecular
endpoints such as developmental genetic heat maps will lead to
further advances.
Another approach to minimize studies on compounds that will
not reach late development is to delay the timing of certain studies
until phase III or even phase IV (post marketing commitment). An
Fig. 6. Assessing effects on male reproduction in non-human primate chronic toxicity studies. The study design shown is relevant for a 3 month study but the approach is also
applicable to 6 and 9 month studies. See also Table 3. d, days.
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timing of non-clinical DART studies in relation to clinical trials.
Similarly, conducting the PPND study in phase III or even as a
phase IV (post marketing commitment), can further reduce animal
usage simply by eliminating the need for a PPND study for a candi-
date molecule that fails in phase III.4.2. Challenge: it can be difﬁcult to estimate whether reductions in
animal use are real when balancing savings in an individual program
for a speciﬁc compound with overall animal use for a particular
company
4.2.1. Expert solution: consideration of all available approaches within
a program, while ensuring that overall animal use does not increase,
offers a balanced approach
If companies were to tailor their programs to their own devel-
opment needs, by focusing on studies that directly impact and
guide future research directions, overall reductions in animal use
would be maximized. A number of suggestions have been pro-
posed for reducing the number of animals in individual programs,
for instance by adding DART measurements to general toxicology
studies or combining fertility studies with EFD studies. Combining
the male and female fertility study and the EFD study can reduce
animal usage for these two studies in rodents by 20% per com-
pound. This combined design (Fig. 4) is appropriate when antige-
nicity is not an issue (biologicals) and when bioaccumulation of
the drug in the test species is not causing unrealistically high expo-
sure levels during the period of major organogenesis. The issue of
bioaccumulation is important to ensure the EFD study is serving
the purpose for which it is being performed i.e., to advise a preg-
nant woman exposed to a drug on the risk of that exposure. The
combined fertility/EFD design has a longer dosing period and expo-
sures during gestation may be higher than those that would be
achieved from exposure only during pregnancy.
Inclusion of male and female fertility endpoints into standard
28 day or longer general toxicity studies could, in theory, eliminate
the need for a separate male and female fertility study (Barrow,
2009), but timing (when the fertility evaluations need to be con-
ducted) and power issues (number of animals required per group)
make it debatable whether this will lead to an overall reduction in
animal use. Potentially, many more animals will be used to test
candidate drugs that will not enter phase III testing due to fertilityassessment being brought forward in the development path
(Fig. 5).
In certain circumstances, such as for biologicals that are not ac-
tive in any other species and are intended for a patient population
which includes women of child bearing age, it may be necessary to
use the NHP for DART studies (Chellman et al., 2009). The relevance
of the NHP as a test species is determined by tissue cross reactivity
andpharmacology studies for largemolecules or in vitrometabolism
for small molecules. It is not necessary, and generally too difﬁcult
and costly, to perform mating as part of the assessment for male
and female fertility. Instead, the use of sexually mature animals al-
lows reproductive parameters to be included on chronic toxicity
studies (typically the 13 week study). Histopathology and organ
weights for the male and female reproductive organs from the
chronic toxicology study provide an adequate assessment of male
and female fertility without the need to add animals to the basic
study design. Additional surrogate markers such as semen/sperm
analysis, measurement of testicular volume, menstrual cycle evalu-
ations and monitoring of reproductive hormones can be added to
these studies when considered appropriate. Incorporating male
and female reproductive evaluations into a chronic toxicity study re-
duces animal usage by 48–56%, compared with running separate
stand-alone reproductive studies (Figs. 6 and 7, Table 3).
The combination of the EFD and PPND studies into an enhanced
PPND (ePPND) study saves an additional 37.5–50% in NHPs per
program (Fig. 8, Table 4) (Stewart, 2009). No novel data are gener-
ated by conducting a separate EFD study, since external/visceral/
skeletal evaluations are incorporated into the infant evaluations
on the ePPND study.4.3. Challenge: a box checking approach to DART study design does not
allow for ﬂexibility or improved efﬁciency
4.3.1. Expert solution: through applied/proactive decision-making,
implementation of new technologies, and differentiation of compounds
by their potential to cause toxicity, fewer studies may be needed to
appropriately assess risk
There are a number of suggestions for how programs could be
conducted differently, rather than adhering to the status quo.
These include situations where compounds have less risk, e.g.
known low toxicity, use of micro-sampling techniques and/or re-
use of animals where appropriate.
Fig. 7. Assessing effects on female reproduction in non-human primate chronic toxicity studies. The study design shown is relevant for a 3 month study but the approach is
also applicable to 6 and 9 month studies. See also Table 3. NHP, non-human primate; LH, luteinizing hormone; FSH, follicle stimulating hormone; EOD, end organ damage.
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exposure (little to no absorption), male and female fertility, EFD
and PPND studies may be incorporated into a single study as cov-
ered in ICH S5. This study design would reduce animal use by
about 50% (Tables 5 and 6).
As mentioned previously, DRF EFD studies in pregnant rodents
and/or rabbits are used to ensure appropriate dose selection for
the full EFD studies. Dosing a small number of animals per group
and evaluating the uterine contents ensures that the dose levels se-
lected produce sufﬁcient numbers of offspring for an appropriate
assessment of developmental toxicity in the full EFD study. If TK
evaluations are included in the DRF-EFD studies, decisions based
on blood concentration levels, which improve species extrapola-
tion, will ensure relevant dose selection. For rabbits, conducting
these DRF-EFD studies in accordance with GLP regulations can
eliminate the need for a full TK proﬁle in the EFD study, reducing
the number of rabbits in each EFD study by at least 10%, with even
further reductions if satellite animals are not used for blood collec-
tion in the DRF-EFD.
The use of micro-sampling and dried blood spot analysis tech-
niques (Jonsson et al., 2012; Spooner, 2010)will enable an increased
number of blood samples to be taken without an additional welfare
burden on the animal, further limiting the number of animals re-
quired per study and compound. In NHP studies, these techniques
would also enable hormone analysis if deemed appropriate, e.g., as
part of male or female reproduction evaluations.
The reuse of animals may also provide an opportunity for over-
all reduction in animal use. However, this must be balanced care-
fully with the overall welfare burden on the individual animal that
is being reused. There are a number of situations where reuse may
be possible without compromising welfare. For instance, a rat
PPND study generates many F1 generation animals that are not
further evaluated post weaning. With 20 litters in each group
and an average of 12 pups in a litter, there are approximately
200 control pups that could be used for the conduct of a DRF-juve-
nile toxicity study or a full juvenile toxicity study (Bailey et al.,
2009).
The recent ICH S6 (R1) addendum allows for reuse of the vehi-
cle-control treated maternal animals from PPND/ePPND studies
using NHPs. Logistically, this procedure must be properly managed
to avoid possible issues that may impact the results of subsequent
studies. For example, maternal animals would have already deliv-ered at least one offspring, and several factors may differ in second
or third pregnancies such as abortion rate, maternal/offspring
interaction, and percent infant survival. To avoid these complica-
tions, animals must be randomly assigned across dose groups in
any future studies. To balance the opportunities to reduce animal
use with welfare concerns of being kept on study for long periods
of time, reuse would be limited to 2–3 pregnancies and/or a max-
imum age (e.g., 15 years) and should take into account the ability
of individual animals to cope with multiple pregnancies.5. Use of rodent models for safety assessment of biologics: how
can we get the most informative data?
ICH S6 guidance covers species selection in the preclinical test-
ing of biologics and deﬁnes a relevant animal species as one in
which the test material is pharmacologically active, based on
expression of the target receptor/epitope and ability to elicit antic-
ipated biological activity. For biologics, particularly monoclonal
antibodies (mAbs), the NHP has often been the only relevant, phar-
macologically active animal model for nonclinical safety evalua-
tion. However, the numbers of novel therapeutics with cross-
reactivity in both rodents and NHPs is increasing; therefore, rodent
use to support IND-enabling toxicity programs has become more
frequent. The June 2011 ICH S6 Addendum further outlines condi-
tions wherein a rodent model may be appropriate for safety eval-
uations of biologics, including:
(1) When test material is pharmacologically active in both a
rodent and non-rodent species, both would be used for short
term studies (<1 month); but rodent alone could be used for
longer term studies if results from shorter term studies in
both species are similar or ﬁndings are understood from a
mechanism of action of the product, unless there is a scien-
tiﬁc rationale to use the non-rodent species.
(2) When no pharmacologically relevant species exists, it may be
feasible to use an appropriate transgenic rodent model or
homologous proteinwith rodent cross-reactivity, if available.
Considering these recommendations and their potential impli-
cations for increased rodent studies for biologics, optimized study
designs are needed to enable full evaluation of toxicity while also
Table 3
Incorporation of reproductive evaluation into chronic toxicity study vs. stand-alone studies.
Group Treatment group Stand-alone M or F reproduction study Chronic toxicity study with reproduction endpoints added
No. main study (M or F) No. recovery (M or F) No. main study (M or F) No. recovery (M or F)
1 Control 5 3 3/3 or 5/5 2/2
2 Low 5 3/3 or 5/5 2/2
3 Mid 5 3/3 or 5/5 2/2
4 High 5 3 3/3 or 5/5 2/2
Stand-alone studies use 26 animals/sex, studies can be reduced by 52 NHPs through incorporating the reproductive evaluations into a chronic toxicity study (48–56%
reduction, depending on group size for chronic study).
Fig. 8. Enhanced peri-postnatal toxicity study for non-human primates (Stewart, 2009). GD, gestational day; PP, post-partum; M, months; Eval, evaluation.
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This section focuses on the safety assessment of a mAb in rat, with
the assumption that the antibody showed similar cross-reactivity
across humans, NHPs, and rats. The considerations proposed could
also be applied to mice, with some additional species-speciﬁc con-
siderations (i.e. difference in available blood volume).
5.1. Challenge: the number of endpoints needed to support regulatory
expectations and enable robust safety evaluation of biologics in
rodents increases the use of animals
5.1.1. Expert solution: investigations of these endpoints in preliminary
studies can inform whether they need to be included in later studies
(e.g. IND-enabling)
Standard assessments for biologics require repeated blood col-
lections, clinical pathology, TK and anti-drug antibody (ADA) anal-
yses to conﬁrm systemic exposure of drug and support correlation
of exposure levels with identiﬁed toxicities. According to ICH S6,
both TK and ADA sampling should be incorporated into study de-
signs to assist in the interpretation of results, due to the potential
for development of immunogenicity following administration of an
exogenous protein (the biologic). Incorporation of pharmacody-
namic (PD) parameter(s), when available, may also be important
to conﬁrm expected on-target biological activity and assess the
predictive capability of the rodent model (for example, cytokine
analysis to evaluate potential immunomodulatory effects).The multiple blood samples planned over the course of a study
can, however, result in a large cumulative demand on blood vol-
ume that must be balanced with the potential impact on animal
welfare and hematological data (e.g., decreased red blood cell mass
and hematocrit, compensatory increases in reticulocytes), particu-
larly in rodent species (Jain, 1987; McGuill, 1989; BVA/FRAME/
RSPCA/UFAW, 1993; Van Herck et al., 1992; Hawk and Leary,
1995; Podolsky and Lukas, 1998; Diehl et al., 2001; Deng et al.,
2011). Historically, this limitation on available blood volumes has
been met through the use of satellite dosing groups speciﬁcally as-
signed for TK or PD assessment, leading to substantial increases in
total animal use per study depending on the number of endpoints
evaluated and blood volume required.
In order to eliminate the need for satellite TK groups in rodent
GLP toxicity studies, the frequency of TK sampling and/or TK sam-
ple volumes must be reduced. A typical characteristic of the PK
proﬁle of biologics is their long half-life. Therefore, traditional sam-
pling schedules employed in safety assessment of small molecules
(i.e., several timepoints on Day 1 and repeated at the end of the
dosing period) may be unnecessary. PK proﬁles derived from single
dose PK studies can be used to optimize TK sampling and limit the
number of collections in subsequent GLP toxicology studies, in
which only periodic conﬁrmation of the expected biologic drug
exposure levels are needed. Using this approach, single dose PK
studies would be utilized to provide full mAb exposure proﬁles
and support human dose projections, rendering extensive TK
Table 4
Animal numbers saved by conducting an enhanced pre-postnatal development study.
Group Treatment group No. EFD study (pregnant F) No. PPND study (pregnant F) No. ePPND study (pregnant F)
1 Control 12–14 16–18 16–18
2 Low 12–14 16–18 16–18
3 High 12–14 16–18 16–18
By conducting one ePPND study instead of two separate studies (EFD and PPND) NHP use can be reduced by 36–42 animals (37.5–50% reduction).
Table 5
Rodent and rabbit developmental toxicity studies.
Study type F0 Generation Embryos/fetuses F1 Generation Embryos/fetuses
DR – RAT II 24 264 – –
RAT I 200 1200 – –
RAT II 100 1200 – –
RAT III 100 1200 200 1200
DR – Rabbit II 24 200 – –
Rabbit II 80 800 – –
528 4864 200 1200
Total animal use using this study design is 6792.
Table 6
Rodent and rabbit developmental toxicity studies.
Study type F0 Generation Embryos/fetuses F1 Generation Embryos/fetuses
DR – RAT II 24 264 – –
RAT I/II 200 1200 – –
RAT III 100 1200 200 1200
DR – Rabbit II 24 200 – –
Rabbit II 80 800 – –
428 3664 200 1200
By combining segment I and II into a single study, rodent and rabbit use can be reduced by about 50%.
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demands would in turn eliminate the need for satellite animals,
and ultimately lead to substantial reductions in overall animal
use. Further, pilot repeat dose toxicity evaluations (e.g. 2–3 repeat
doses) conducted prior to a full GLP study can serve to elucidate
potential immunogenicity risk, and in some cases may support
elimination of the rodent as an appropriate species for toxicity
evaluation (e.g. where ADA responses substantially attenuate
and/or obviate both drug exposure and PD biomarker activity).5.2. Challenge: correlation of exposure/activity endpoints (TK and PD)
to toxicity assessments
5.2.1. Expert solution: reduce the number of blood collection time
points to allow sampling for exposure, functional/translational
biomarkers, and toxicity endpoints to be obtained from the same
animals
Satellite groups for TK and PD enable collection of these end-
points while staying within blood volume limits for any given ani-
mal, and also reduce the potential for confounding factors that may
be associated with repeated blood collection on clinical pathology
or other safety parameters. However, use of satellite animals can
limit data interpretation, as safety and TK/PD/ADA endpoints are
characterized in different sets of animals and individual correla-
tions of toxicity/exposure relationships are not possible.
Where feasible, sampling frequencies for TK/PD/ADA endpoints
should be reduced to enable integrated assessments from the main
study animals and eliminate the need for satellite groups. Although
relatively frequent post-dose sampling may be necessary to char-
acterize TK for small molecules with rapid clearance, the inclusion
of multiple time points over a short duration generally does not
add value for biologics. For biologics with expected PK proﬁles(ideally characterized in a pilot non-GLP PK study, showing linear
clearance and a relatively long half-life), TK sampling could be lim-
ited to 3–4 time points following the ﬁrst and last dose and still en-
able adequate assessment of exposure, thereby reducing the need
for satellite TK groups. Sampling should occur at the same intervals
for all animals, including controls, to eliminate potential bias. In
speciﬁc cases where additional TK and/or PD time points are con-
sidered necessary based on preliminary data to achieve study
objectives, satellite groups may be used on a limited basis to sup-
port sampling needs (Table 7).
Samples for ADA analysis are typically collected after some
interval following the ﬁrst dose to allow adequate time for a posi-
tive ADA response to appear. Frequent ADA sampling over the dos-
ing period is generally uninformative, as circulating drug levels are
typically high and may interfere with accurate ADA detection.
Therefore, a limited ADA sampling schedule is recommended. For
example: once pretreatment, once or twice mid-study, at termina-
tion of the treatment period and periodic sampling during the
recovery period, when circulating drug levels are decreasing.
With satellite groups, composite sampling strategies (where
proﬁles are made up from multiple animals) generate an average
TK/PD proﬁle for a given dose level. Although this evolved as stan-
dard practice because of the known challenges with blood volume
limitations in rodents, it can introduce greater variability in bio-
marker endpoints by pooling data and preventing direct correla-
tion of exposure-effect relationships within individual animals. If
both exposure and PD information could be obtained from the
main study animals, the ability to make direct correlations with
histopathology and other safety endpoints could increase the
power of toxicity and translational biomarker assessments.
Although satellite animals may still be required under some
circumstances, integration of endpoints into the main study
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interpretation of results. Other approaches that may be considered
include sampling only frommales where no sex difference is antic-
ipated. Due to their larger size, fewer animals can be used for PD/
toxicodynamic and other functional assays. Also, it may be more
appropriate to move toxicodynamic endpoints to later in the study,
to reduce blood requirements during important early sampling
periods (such as the ﬁrst two weeks post dose for TK), particularly
since repeated or durable exposure may be necessary to elicit
meaningful changes in toxicodynamic biomarkers.
Ultimately, a critical evaluation of the speciﬁc needs of each
program, based on target biology and known PK/PD proﬁles, is nec-
essary when designing an IND-enabling toxicity study. The solu-
tions proposed are intended to provide opportunities to reduce
unnecessary or uninformative sample collections, enable reduction
or elimination of satellite groups, and obtain improved data inter-
pretation from main study animals.
5.3. Challenge: large blood sample volume requirements during ﬁrst
week of dosing due to temporal clustering of early endpoints
5.3.1. Expert solution: increase age of rats at study initiation to allow
larger volume of sampling at in the ﬁrst week, or utilize blood
microsampling techniques
One of the biggest challenges to reducing or eventually elimi-
nating TK satellite groups is encountered during the ﬁrst one to
two weeks following ﬁrst dose administration, where characteriza-
tion of the initial exposure proﬁle and/or PD response requires re-
peated blood sampling over a limited period of time. As biological
differences between rats of 6, 8, or 12 weeks of age are primarily
due to increases in overall size, weight and development of sexual
maturity, it may be possible to eliminate satellite groups in rat tox-
icity studies altogether, or at least permit a reduction in the num-
ber of satellite animals required per group, by initiating studies
with rats at 12 weeks instead of 6 weeks of age. At 12 weeks of
age, male and female rats for most commonly used strains are
approximately 225–250 g, allowing collection volumes approxi-
mately 1.5- to 2-fold that of 6 week old animals without adversely
impacting welfare (Lewis et al., 2002). Therefore collection of re-
peated samples is possible from the main study animals if the
blood volume per sample and/or sampling frequency are limited.
Initiation of studies with animals at 12 weeks of age should be
acceptable even in the context of chronic toxicity studies for biol-
ogics (up to 6 months in duration per ICH S6), without concerns
relating to longevity or overall survival for this species. The differ-
ence in blood collection volume between 6 and 12 weeks is less
evident in mice, but still merits some consideration depending
on blood volume requirements deﬁned for the study.
Finally, microsampling and dried blood spot (DBS) procedures
are at the forefront of technological improvements that could re-
sult in signiﬁcant reductions in the numbers of animals needed
and also involve less invasive blood sampling techniques including
tail snip, sublingual vein sampling, and saphenous vein sampling.
These have been developed for the mouse but could equally be ap-
plied to reduce the use of rats. Both microsampling and DBS have
been discussed in detail in the literature (Jonsson et al., 2012;
Spooner, 2010). Overall, this is recognized as an area with great po-
tential to reduce the number of animals needed and increase the
possibility of blood sampling from main study animals. Addition-
ally, reducing blood volume wherever possible has scientiﬁc
advantages, as it minimizes the risk of confounding factors due
to blood withdrawal impacting hematology results. Future work
and investment is needed to validate methods to GLP standards,
in the technologies used to detect and analyze mAbs (as opposed
to chemicals), and in systems that can accommodate microsam-
pling for hematology and clinical chemistry evaluation. Whenconsidering all possible study designs, a 30% reduction in study
populations may be achieved while optimizing the value of the
information obtained. In addition to minimizing the number of
animals used, stress induced by blood sampling techniques should
also be taken into consideration. Sampling methods and frequency
can be selected to minimize stress responses and any related effect
on study outcome, especially if sampling only main study animals
(Sparrow et al., 2011).6. Learning from experiences: a case study in the agrochemical
sector
In addition to the pharmaceutical industry, other sectors are
also required to conduct toxicology studies to support health pro-
tection, and are faced with similar challenges that drive the devel-
opment of more efﬁcient and less animal-dependent tools for
safety testing. Sharing of experiences and practices across sectors
is mutually beneﬁcial in the identiﬁcation of novel ways of improv-
ing practice. The workshop and further work presented here in-
cluded the agrochemical industry perspective to facilitate cross-
sector communication.
Animal use for agricultural chemical testing programs has been
sizeable due to the comprehensive nature of the regulatory frame-
works in place to ensure protection of human health and the envi-
ronment. Prior to registration, pesticides undergo at least 120
health, safety, and environmental tests, many of which use animals
(US EPA, 2007; Croplife America, 2012). In recent years, leaders in
the pesticide industry as well as regulatory agencies have recog-
nized and acted upon opportunities to provide the information
needed to protect human health and the environment while also
applying 3Rs principles. These opportunities have arisen from crit-
ically assessing the value of multiple studies to overall risk assess-
ment, and removing those that are redundant or do not add
signiﬁcant value. In addition, it has been recognized that some
study objectives can be accomplished in a more efﬁcient manner,
for example by combining endpoints into one study that have tra-
ditionally been measured in separate studies.
One noteworthy effort to improve efﬁciency of testing pesti-
cides was the ILSI-HESI Agricultural Chemicals Safety Assessment
(ACSA) project (Carmichael et al., 2006; Barton et al., 2006; Doe
et al., 2006; Cooper et al., 2006). The objective was to provide a
new testing paradigm for crop protection chemicals by developing
more relevant studies that use fewer animals. Signiﬁcantly, one
major conclusion generated from the retrospective evaluation of
best approaches for assessing systemic toxicity was that the one
year dog and mouse carcinogenicity studies did not add signiﬁcant
value, and should no longer be required. Also, it was determined
that an extended one generation reproductive toxicity study could
be used in place of a multi-generation study and an appropriate
test guideline was recently adopted (OECD, 2011). If fully realized,
the ACSA proposals have the potential to reduce animal use for
pesticide toxicity studies by up to 65% (Carmichael et al., 2006,).
While some proposals have not been fully adopted, signiﬁcant pro-
gress has been made with the one year dog and the extended one
generation reproductive toxicity studies.
The pesticide industry is taking further steps to proactively
adopt other improvements in study design intended to improve
data reliability and also reduce and/or reﬁne animal use. For exam-
ple, the USEPA functional immunotoxicity study can be success-
fully combined with either 28-day or 90-day repeat-dose toxicity
studies, thus eliminating the need for a stand-alone study (Ladics
et al., 1995; Ladics et al., 1998; Terry, 2011).
Similarly, US EPA neurotoxicity requirements can also be ful-
ﬁlled using a combined or integrated testing approach. In fact, both
the immunotoxicity and neurotoxicity requirements can be met
Table 7
Optimization of rat study design for large molecules.
Traditional designs – toxicity
populations
Plus TK/ADA and PD satellite
populations
Older animals toxicity populations –
no change
Optimized approach*
Animals/group main
study
10 Control = 3/sex test article
groups = 12/sex
10 3/sex for TK/ADA for all
groups
Number sexes 2 2 2 2
Number groups 4 4 4 4
Animal/group
recovery
5 Groups 1 and 4 – 5 Groups 1 and 4 –
Total animals 100 78 100 24
Overall Total Savings of 54 animals
* Samples for PD collection from main study animals, TK/ADA population reduced by use of older/larger animals allowing access to greater blood volumes/animal and
reducing number of time points based on understanding of molecule kinetics (large molecules).
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ble 8). The integration of TK into repeat-dose toxicity studies pro-
vides information on exposure which supports translation of
animal data, used in conjunction with human biomonitoring data,
to provide a more accurate and complete understanding of risk
(Aylward and Hays, 2008). Also, taking steps to establish internal
dosimetry can help avoid unrealistic exposure scenarios (i.e. non-
linear kinetics) in animal toxicity tests, thus minimizing the poten-
tial for pain and suffering while simultaneously obtaining more
relevant and reliable data (Creton et al., 2011). Other examples of
proactive steps taken by the crop protection industry to apply
the 3Rs include: integration of in vivo genotoxicity (e.g. micronu-
cleus) into repeat-dose dietary studies, preservation of contin-
gency tissues from repeat-dose studies for follow-up mode-of-
action work (Geter et al., 2011), and utilization of dietary route
of exposure for studies traditionally conducted by oral gavage
(i.e. developmental toxicity) (Rasoulpour et al., 2012) (Table 9).
In addition, signiﬁcant improvements have been made towards
advancement of 3Rs principles and goals in the conduct of acute
toxicity studies (e.g. acute oral, acute dermal, acute inhalation, skin
and eye irritation, skin sensitization) for agrochemical active ingre-
dients and formulations (Creton et al., 2010; Seidle et al., 2010;
Price et al., 2011; Stallard et al., 2012). Such studies are required
by regulatory agencies for the purpose of identifying acute hazards
which serve to inform classiﬁcation and labeling of end-use prod-
ucts with the ultimate goal of protecting human health. Speciﬁc
advances have been accomplished by recognizing opportunities
to eliminate unneeded studies through data waivers or by bridging
to existing studies on similar materials. In addition, signiﬁcant ad-
vances have been made through adoption of modern study guide-
lines (e.g. Local Lymph Node Assay (LLNA), ﬁxed/limit dose
approaches) designed to minimize animal use and improve animal
welfare while providing the information needed for classiﬁcation
and labeling and protection of human health. In the future, many
potential opportunities exist for eventual replacement of in vivo
acute toxicity studies with in vitro alternatives.
One signiﬁcant challenge to more systematic adoption of 3Rs
principles and overall reductions in animal use in the pesticide
industry is the lack of global harmonization in pesticide data
requirements. For example, based on the results of a retrospective
analysis, the one year dog study was recently shown to add no sig-
niﬁcant value beyond data generated from the 90-day study (Del-
larco et al., 2010; Kobel et al., 2010). Accordingly, this study was
removed as a core data requirement in the US and EU. However,
until other regulatory agencies follow suit, registrants continue
to conduct the one year study for new pesticide active ingredients
intended for global markets. It was also recently shown that the
mouse carcinogenicity study does not contribute signiﬁcantly to
the derivation of reference doses or hazard classiﬁcation, and thus
could also be removed as a core data requirement; however, regu-
latory agencies have not yet adopted proposals to remove themouse carcinogenicity study as a core data requirement (Billington
et al., 2010).7. Discussion
Scientists face a variety of new challenges in the current eco-
nomic climate that require them to achieve more with less – more
predictive efﬁcacy and safety, with less time, staff and resources.
Often, the topic of reducing animal use is perceived as a European
regulatory issue; however, scientists are increasingly recognizing
the beneﬁts of using the 3Rs as a framework to improve science
and reduce costs. The workshop and subsequent discussions in this
paper focused on areas with US strengths and interests to make
drug development more efﬁcient while minimizing animal use.
Many new technologies and approaches are being developed to
advance toxicological science, but there is a time lag before these
are routinely integrated into drug development. The ﬁeld is moving
rapidly and the most efﬁcient way to incorporate this knowledge
into industry processes is for company experience to be shared, en-
abling the selection of the most promising methods and rapidly
identifying those that have not delivered. This would also take
advantage of the current era of open innovation where companies
are much more willing to sharing precompetitive knowledge. The
National Centre for the 3Rs in the UK has provided ‘neutral broker-
age’ for pre-competitive sharing of 3Rs advances in Europe and has
also launched CRACK IT, an open innovation programme in the 3Rs.
The recently formed International Consortium for Innovation and
Quality in Pharmaceutical Development’s (IQ Consortium) 3Rs
Leadership Group provides a similar platform for data sharing in
the US.
This is particularly pertinent in the area of in vitro predictive
toxicology where a shift is needed in how in vitromethods are per-
ceived. Consensus must be agreed on the criteria for an in vitro test
to be considered successful, not just in replacing in vivo assays, but
also in predicting certain mechanisms of toxicity. Once current
in vitro methods are fully leveraged, we need to ensure that the
animal models we are using are adding value to the integrated risk
assessment. There are approaches described in this paper that
could reduce the number of studies needed for compounds (i) with
low toxicity, (ii) that are intended for acute, high risk indications or
(iii) that may be dropped later in development. Additionally, there
are advances that could be made in study design, for instance using
new technologies to achieve adequate statistical power without
increasing the number of animals, combining studies, and improv-
ing use of TK data to optimize dose selection.
What is needed to accelerate progress in this area? We believe
that a three-step approach is needed. First, an industry champion
working with relevant company scientists is needed to
lead and build the evidence base for changes in practice. This
champion would also be tasked with working with relevant trade
Table 8
Animal use in combined 90 day study.
Traditional 90-day (OECD 408) Stand-alone immunotoxicity Stand-alone 90-d neurotoxicity Integrated approach
Animal/group 10 8 10 10 (5/sex for +cont)
Number sexes 2 1 2 2
Number groups 4 5 4 4
Total animals 80 40 80 90
Overall total 80 + 40 + 80 = 200 Savings of 110 animals
Table 9
Examples of 3Rs advances and innovationsin the agriculture chemical industry.
Example Driver Challenges
Removal of one year dog requirement in US and EU ACSA recommendations; further evaluation by US EPA,
industry
Continues to be a requirement in some
countries
Proposed removal of mouse carcinogenicity data
requirement
ACASA recommendations; further evaluation by industry Reluctance by agencies to remove
requirement
Integration of US EPA – speciﬁc requirements
(immunotoxicity, neurotoxicity) into 90-day
Industry innovation; desire to combine up to 3 studies into 1 Promotion of concept to other industry
members and regulatory agencies
Integrated toxicokinetics ACSA recommendations; need to establish internal dosimetry Potentially extra cost associated, but can
often prevent future cost
Dietary development toxicity ACSA recommendations; use relevant exposure route,
continuous exposure, reduced vehicle confounding
Overcoming convention (gavage)
Integrated in vivo genotoxicity Relevant route (dietary), reduced animal use, more precise Overcoming convention (stand-alone
gavage)
Preservation of tissues Frequent need to determine if toxicological MoA is relevant to
humans without unnecessary animal use
Requires planning ahead and cannot always
predict
K.L. Chapman et al. / Regulatory Toxicology and Pharmacology 66 (2013) 88–103 101associations and professional societies to increase awareness of the
importance and implications of speciﬁc scientiﬁc advances, includ-
ing advances in our understanding of the relative utility of speciﬁc
animal models/studies to predict human safety. Second, greater
global interaction with regulators on new approaches is essential
to advance risk assessment in the chemical and pharmaceutical
industries and achieve better harmonization. Third, a global com-
mitment of companies, academic organizations, and regulators is
needed to take 3Rs out of the ‘competitive arena’ and to commit
to share all that they know and learn, for the beneﬁt of the animals,
as well as human patients and clients.
The authors conclude that there are many unrealized beneﬁts
and incentives that may be realized by employing a scientiﬁc ap-
proach to review and reﬁne animal use. If the suggestions in this
paper were implemented widely, there is a realistic near-term po-
tential for signiﬁcant reductions in animal use. Importantly, pro-
gressive approaches to toxicological science will lead to better
prediction of human safety with reduced attrition of compounds
under development.
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